Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director · President and CEO | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2034-01-31 | Direct | 500,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 21, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 14,765 | $60.63 | $895,201.95 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.31 to $61.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 15,235 | $59.82 | $911,357.70 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,558 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.31 to $60.30 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-21-052744 · doc4.xml · derivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,846 Underlying: Common Stock · 20,000 shares Expires 2025-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 20,000 | $88.01 | $1,760,204.00 |
DisclosureSEC source: 0001209191-21-052744 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 20,000 | $4.84 | $96,700.00 |
DisclosureSEC source: 0001209191-21-052744 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · derivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,846 Underlying: Common Stock · 20,000 shares Expires 2025-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 30,000 | $85.28 | $2,558,538.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 20,000 | $4.84 | $96,800.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · derivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,600 | $86.90 | $139,044.16 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $86.76 to $87.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 21,773 | $86.19 | $1,876,710.67 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,393 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $85.76 to $86.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 6,627 | $85.38 | $565,820.55 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,166 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $84.76 to $85.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0000899243-21-029868 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-21-035301 · doc4.xml · derivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,846 Underlying: Common Stock · 20,000 shares Expires 2025-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 20,000 | $77.16 | $1,543,292.00 |
DisclosureSEC source: 0001209191-21-035301 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 20,000 | $4.84 | $96,700.00 |
DisclosureSEC source: 0001209191-21-035301 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 5,154 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · derivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,846 Underlying: Common Stock · 5,154 shares Expires 2025-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 14,846 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,846 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · derivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 30,000 | $85.24 | $2,557,284.00 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 5,154 | $4.84 | $24,919.59 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 14,846 | $6.62 | $98,280.52 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · derivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 30,000 | $85.54 | $2,566,212.00 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-21-028259 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · derivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 20,000 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Not applicable. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 5,547 | $103.16 | $572,205.78 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $102.86 to $103.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 8,602 | $102.26 | $879,661.16 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,340 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $101.85 to $102.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,602 | $101.42 | $263,883.39 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,942 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $100.83 to $101.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,848 | $100.48 | $185,690.92 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,544 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $99.825 to $100.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,401 | $99.08 | $138,816.96 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,392 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $98.65 to $99.645 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 20,000 | $6.62 | $132,400.00 |
DisclosureSEC source: 0001209191-21-012326 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 20 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,846 Underlying: Common Stock · 20,000 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 19 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,075 | $100.01 | $307,544.90 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 16 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F14 · price: Represents the weighted average sale price of the shares sold ranging from $99.81 to $100.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 6,520 | $99.35 | $647,732.01 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 15 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,868 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F13 · price: Represents the weighted average sale price of the shares sold ranging from $98.80 to $99.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 7,638 | $98.45 | $751,951.93 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 14 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,388 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F12 · price: Represents the weighted average sale price of the shares sold ranging from $97.80 to $98.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 12,767 | $97.23 | $1,241,382.65 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 13 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,026 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F11 · price: Represents the weighted average sale price of the shares sold ranging from $96.77 to $97.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 20,000 | $6.62 | $132,400.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 12 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 11 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 18 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F16 · price: Not applicable. F17 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 200 | $106.96 | $21,391.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F10 · price: Represents the weighted average sale price of the shares sold ranging from $106.84 to $107.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 645 | $106.03 | $68,391.80 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,993 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F9 · price: Represents the weighted average sale price of the shares sold ranging from $105.75 to $106.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 4,271 | $105.25 | $449,516.77 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,638 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $104.75 to $105.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 9,156 | $104.13 | $953,438.09 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,909 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $103.74 to $104.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,895 | $103.23 | $402,085.91 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,065 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $102.71 to $103.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.